Our Technologies

At Tikva Allocell, we leverage on robust and proven EBVST platform combined with our proprietary strategy to promote safe and highly efficacious treatments.

Our Technologies

Diverse Strategies
One Goal


Allogeneic EBVST

Well tolerated and able to be enhanced with novel strategies to improve efficacy, persistence and safety.


Solid Tumor Target

Focused on unmet medical need which has the greatest potential to benefit from novel CAR-T technology.


Oncolytic Virus

Enhanced tumor killing through modification of tumor microenvironment to further improve T cell efficacy.

Preventing Graft vs Host Disease (GvHD)

Allogeneic EBVST​

We leverage on the robust Epstein-Barr Virus Specific T (EBVST) Cell platform to reduce graft-versus-host diseases (GvHD) without the need for genetic editing. This is critical in enabling infusion of allogenic CAR-T cells for ‘off-the-shelf’ therapy.

Building on the EBVST platform, it can be engineered to express chimeric antigen receptors, safety switches, decoy receptors and pro-survival molecules.

Focus on unmet need

Solid Tumor Target

Our CAR-T cells are engineered to target solid tumor antigens that correlate with aggressive biology, low tumor-infiltrating T-lymphocyte density, and poor prognosis. 

Our CAR-T cells are also protected from allogenic rejection of CAR-T cell by host using various pathways to improve persistence of the infused CAR-T cells (survival of CAR-T cells after infusion) and ensure durable response.

Enhancing tumor killing

Oncolytic Virus

Replication-deficient adenovirus infect tumor cells and modify the tumor micro-environment (TME) to enhance efficacy of CAR-T cells in ‘cold’ solid tumors. 

Helper-dependent adenovirus deliver genetic payloads to instruct the tumor cells to produce pro-proliferation cytokines and/or antibodies that inhibit T cell exhaustion, allowing our CAR-T cell to survive and function in hostile TME.

Oncolytic adenovirus increases tumor immunogenicity (ability to elicit an immune response) via direct lysis and release of tumor antigens.